Tybourne Capital Management
VC Fund
Hong Kong, Hong Kong
Tybourne Capital Management is a VC fund in Hong Kong focused on Biotechnology and Pharmaceutical. Tybourne is a global investment firm with a fundamental approach to equity investing, both public and private
- Total investments:
- 26
- Last investment:
- Lead investor:
- 19%
Last updated:
For AI agents: llms.txt
Industries Tybourne Capital Management invests in
Stages Tybourne Capital Management invests in
Countries Tybourne Capital Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bosun Hau
|
|||
Eashwar Krishnan
|
|||
Investment Focus
Industry
- Biotechnology 8 (31%)
- Pharmaceutical 5 (19%)
- Payments 3 (12%)
- Health Care 3 (12%)
- Energy 2 (8%)
Stage
- Series C 8 (31%)
- Series B 6 (23%)
- Series D 4 (15%)
- Series A 2 (8%)
- Series E 1 (4%)
Country
- United States 5 (19%)
- India 3 (12%)
- Japan 3 (12%)
- China 2 (8%)
- United Kingdom 2 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bosun Hau
Managing Director | Co-Head of Private Investments
|
Managing Director | Co-Head of Private Investments | Total investments: 5 | Find email | |
|
Eashwar Krishnan
Managing Partner, CEO & CO-Founder
|
Managing Partner, CEO & CO-Founder | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cambridge Photon Technology
|
Cambridge Photon Technology is a developer of organic photovoltaic devices used to enhance next-generation solar technology. Its devices engage in the deployment of off-grid solar power and use advanced nanotechnology to split each incoming blue and green photon into two infra-red photons that enable clients to deploy solar power throughlightweight devices whenever needed. | $1.2M / Nov 06, 2025 | |
Wugen
|
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cellmalignancies. | $115M / Series C / Aug 27, 2025 | |
Forte Biosciences
|
Forte Biosciences is a biotechnology company that focuses on dermatology. The company's lead product, FB-401, is a topically applied live biotherapeutic developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases for the treatment of inflammatory skin disease. | $53M / Post-IPO Equity / Nov 20, 2024 | |
SkyCell
|
SkyCell is a Swiss-based, award-winning provider of temperature-controlled container solutions with a special focus on serving global pharma companies and sustainability. They are driven by their mission to supply the safest pharma containers worldwide. This is achieves through their unique combination of hardware, software and service, whichenables us to master logistical challenges and eliminate temperature excursion. | $59M / Series D / Jun 25, 2024 | |
ASUENE
|
Asuene involves in clean power retail business, retail SaaS business, etc. | $26.7M / Series C / Jun 14, 2024 | |
|
Forte Biosciences
|
Forte Biosciences is a biotechnology company that focuses on dermatology. The company's lead product, FB-401, is a topically applied live biotherapeutic developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases for the treatment of inflammatory skin disease. | $25M / Post-IPO Debt / Aug 01, 2023 | |
Clove Dental
|
Clove Dental offers a comprehensive set of oral healthcare services, leverages best-in-class equipment, and utilizes the latest pain-management technology. Clove Dental has recruited over 800 dentists and set the highest thresholds for hygiene, clinic safety, transparency, ethics, and customer service. Spread across 350+ clinics, Clove manages anexcess of 1 million + patients every month. | $67M / Series D / Nov 09, 2022 | |
|
ASUENE
|
Asuene involves in clean power retail business, retail SaaS business, etc. | $17.5M / Series B / Sep 14, 2022 | |
ACELYRIN
|
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients. | $300M / Series C / Sep 13, 2022 | |
Kopi Kenangan
|
Kopi Kenangan is one of several grab-and-go coffee chains trying to capitalize on the rising trend and demand for grounded coffee beverages in a country which has the lowest coffee consumption per capita in the region, despite being the world’s fourth-largest coffee exporter. | $96M / Series C / Dec 27, 2021 | |
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Tybourne Capital Management invest in?
Tybourne Capital Management invests primarily in Biotechnology, Pharmaceutical and Payments startups, most often at Series C and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tybourne Capital Management?
Public channels for Tybourne Capital Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tybourne Capital Management?
The team at Tybourne Capital Management includes Bosun Hau (Managing Director | Co-Head of Private Investments) and Eashwar Krishnan (Managing Partner, CEO & CO-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
